Author

L. Kliker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

I. Nemet· 2 shared M. Aftalion· 2 shared M. Mandelboim· 2 shared N. Paran· 2 shared T. Chitlaru· 2 shared T. Israely· 2 shared A. Bercovich-Kinori· 1 shared A. Beth-Din· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

I. Nemet

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR screens for host factors critical for infection by SARS-CoV-2 variants of concern identify GATA6 as a central modulator of ACE2.

M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori

This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.

bioRxiv · Jul 19, 2021 · PreprintMicrobiology

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants

E. Makdasi, A. Zvi, R. Alcalay, T. Noy-Porat, E. Peretz, A. Mechaly, Y. Levy, E. Epstein, T. Chitlaru, A. Tennenhouse, M. Aftalion, D. Gur, N. Paran, H. Tamir, O. Zimhony, , R. Rosenfeld

This study evaluates the neutralization potency of four SARS-CoV-2 mAbs against spike mutations and two variants of concern, finding that MD65 and BL6 retain effectiveness against B.1.1.7 and B.1.351.

bioRxiv · Apr 1, 2021Immunology